uniQure (NASDAQ:QURE) Price Target Raised to $110.00 at HC Wainwright

Key Points

• HC Wainwright has increased uniQure's price target from $70.00 to $110.00, indicating a potential upside of 100.29%.
• Several analysts have revised their price targets for uniQure, with estimates ranging from $68.00 to $95.00, showcasing strong support for the stock.
• Insiders sold a total of 244,316 shares of uniQure over the last 90 days, raising concerns about insider confidence despite the stock's recent price movements.

uniQure (NASDAQ:QURE - Get Free Report) had its price target boosted by stock analysts at HC Wainwright from $70.00 to $110.00 in a research note issued on Monday,Benzinga reports. The firm currently has a "buy" rating on the biotechnology company's stock. HC Wainwright's price objective points to a potential upside of 100.29% from the stock's current price.

A number of other analysts have also weighed in on the stock. Leerink Partners raised their target price on shares of uniQure from $48.00 to $68.00 and gave the company an "outperform" rating in a research report on Wednesday, September 24th. Chardan Capital increased their price target on uniQure from $35.00 to $76.00 and gave the company a "buy" rating in a research report on Thursday, September 25th. UBS Group set a $95.00 price target on shares of uniQure in a research report on Thursday, September 25th. Wells Fargo & Company lifted their price objective on shares of uniQure from $65.00 to $80.00 and gave the company an "overweight" rating in a research note on Thursday. Finally, Cantor Fitzgerald raised their price target on uniQure from $47.00 to $80.00 and gave the company an "overweight" rating in a report on Thursday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $71.75.

uniQure Price Performance

uniQure stock opened at $54.92 on Monday. The business has a 50-day moving average of $21.59 and a 200-day moving average of $16.40. uniQure has a 1 year low of $4.82 and a 1 year high of $60.70. The firm has a market capitalization of $3.01 billion, a P/E ratio of -14.01 and a beta of 0.56. The company has a current ratio of 9.98, a quick ratio of 9.98 and a debt-to-equity ratio of 1.53.

uniQure (NASDAQ:QURE - Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.20. The firm had revenue of $5.26 million for the quarter, compared to the consensus estimate of $5.00 million. uniQure had a negative return on equity of 1,010.74% and a negative net margin of 1,387.98%. On average, equities analysts anticipate that uniQure will post -3.75 EPS for the current year.

Insider Transactions at uniQure

In related news, CEO Matthew C. Kapusta sold 226,316 shares of the firm's stock in a transaction that occurred on Wednesday, September 24th. The stock was sold at an average price of $41.46, for a total value of $9,383,061.36. Following the transaction, the chief executive officer directly owned 651,454 shares of the company's stock, valued at approximately $27,009,282.84. This trade represents a 25.78% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Christian Klemt sold 15,000 shares of the business's stock in a transaction on Friday, September 26th. The stock was sold at an average price of $55.00, for a total transaction of $825,000.00. Following the transaction, the chief financial officer directly owned 217,730 shares in the company, valued at $11,975,150. This trade represents a 6.45% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 244,316 shares of company stock worth $10,328,181 over the last 90 days. 4.79% of the stock is owned by insiders.

Institutional Trading of uniQure

A number of institutional investors have recently bought and sold shares of QURE. Jefferies Financial Group Inc. acquired a new stake in uniQure during the 2nd quarter worth approximately $29,217,000. Vestal Point Capital LP boosted its position in shares of uniQure by 58.4% during the first quarter. Vestal Point Capital LP now owns 4,792,572 shares of the biotechnology company's stock valued at $50,801,000 after buying an additional 1,767,572 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in uniQure by 471.7% during the second quarter. JPMorgan Chase & Co. now owns 1,807,685 shares of the biotechnology company's stock worth $25,199,000 after purchasing an additional 1,491,486 shares during the last quarter. Sofinnova Investments Inc. increased its holdings in uniQure by 185.5% during the second quarter. Sofinnova Investments Inc. now owns 1,558,356 shares of the biotechnology company's stock worth $21,723,000 after buying an additional 1,012,585 shares during the last quarter. Finally, Aberdeen Group plc raised its stake in uniQure by 46.8% in the 1st quarter. Aberdeen Group plc now owns 2,215,551 shares of the biotechnology company's stock valued at $23,485,000 after acquiring an additional 706,216 shares during the period. Institutional investors own 78.83% of the company's stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.